41024-91-3

Basic information

• Product Name: PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE
• Synonyms: PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE;PENTAETHYLENE GLYCOL DI-P-TOLUENESULPHONATE;PENTA(ETHYLENE GLYCOL)DI-P-TOSYLATE;PENTAETHYLENE GLYCOL DITOSYLATE;3,6,9,12-TETRAOXATETRADECANE-1,14-DIYL DITOSYLATE;Pentaethylene glycol di-p-tosylate~3,6,9,12-Tetraoxatetradecane-1,14-diyl di-p-toluenesulphonate;3,6,9,12-tetraoxatetradecane-1,14-diyl di-p-toluenesulfonate;NSC625453
• CAS NO: 41024-91-3
• Molecular Formula: C₂₄H₃₄O₁₀S₂
• Molecular Weight: 546.65
• Product Categories: Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfur Compounds;Tosylates
• Mol File: 41024-91-3.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 661.4°Cat760mmHg
• Flash Point: >230 °F
• Appearance: /
• Density: 1.26 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.26E-16mmHg at 25°C
• Refractive Index: n20/D 1.524(lit.)
• Water Solubility: Not miscible or difficult to mix in water.
• Sensitive: Hygroscopic
• BRN: 3599245
• CAS DataBase Reference: PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE(41024-91-3)
• EPA Substance Registry System: PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE(41024-91-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 41024-91-3(Hazardous Substances Data)

Usage

Description

Tos-PEG6-Tos is a PEG linker containing two tosyl groups. The hydrophilic PEG spacer increases solubility in aqueous media. The tosyl group is a very good leaving group for nucleophilic substitution reactions.

Uses

Different sources of media describe the Uses of 41024-91-3 differently. You can refer to the following data:
1. PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE is used to prepare calix[4]arenes,1 calix[5]arenes,2 and crown ethers.3
2. Pentaethylene glycol di-p-toluenesulfonate is used in the preparation of calix[4]arenes, calix[5]arenes, and crown ethers. It is also used in the preparation of 3?-formylbenzo-18-crown-6 by undergoing coupling reaction with 2,3-dihydroxybenzaldehyde.

InChI:InChI=1/C24H34O10S2/c1-21-3-7-23(8-4-21)35(25,26)33-19-17-31-15-13-29-11-12-30-14-16-32-18-20-34-36(27,28)24-9-5-22(2)6-10-24/h3-10H,11-20H2,1-2H3

Upstream product

• 4792-15-8 Pentaethylene glycol 
• 98-59-9 p-toluenesulfonyl chloride 
• 112-26-5 1,2-bis(2-chloroethoxy)ethane 
• 107-21-1 ethylene glycol 

Downstream Products

• 75507-17-4 benzyl 2,4,7,10,13-pentaoxacyclopentadecan-2-ylmethyl ether 
• 76377-04-3 2-Benzyloxymethyl-1,4,7,10,13,16-hexacyclooctadecan 
• 87681-99-0 3,6-Dimethylbenzo-18-crown-6 
• 98793-00-1 1,14-bis-(o-benzyloxyphenoxy)-3,6,9,12-tetraoxatetradecane 
• 88631-15-6 5,11,17,23-tetrakis(1,1-dimethylethyl)-25,27-dihydroxycalix[4]arene-crown-6 
• 134750-77-9 (-)-cis-4a-Phenyloctahydro-5,8,11,14,17,20-hexaoxabenzocyclooctadecane 
• 134750-77-9 (4aS,20aR)-4a-Phenyl-hexadecahydro-5,8,11,14,17,20-hexaoxa-benzocyclooctadecene 
• 101210-54-2 N-(p-tolylsulphonyl)-1,4,7,10,13,16-hexaoxa-19-azacyclohenicosane 
• 84812-04-4 <(Allyloxy)-methyl>-18-crown-6 
• 177079-12-8 2-Benzyl-5,6,8,9,11,12,14,15,17,18-decahydro-2H-4,7,10,13,16,19-hexaoxa-2-aza-cyclopentacyclooctadecene-1,3-dicarboxylic acid dimethyl ester 
• 244036-52-0 2,23-dibromo-6,7,9,10,12,13,15,16,18,19-decahydro-5,8,11,14,17,20-hexaoxa-dibenzo[a,c]cycloeicosene 
• 548485-25-2 (5S,22S)-8-bromo-30-methoxy-5,22-diphenyl-3,6,9,12,15,18,21,24-octaoxabicyclo[24.3.1]triaconta-1⁽²⁹⁾,26⁽³⁰⁾,27-triene 
• 944346-68-3 C₃₄H₄₂O₆S₄ 
• 1037824-98-8 meso-{3-[14-(pyridin-3-yloxy)-3,6,9,12-tetraoxatetradecyloxy]phenyl}-bis[5-ethoxycarbonyl-4-butyl-3-methylpyrrol-2-yl]methane 

Relevant articles and documents

Synthesis and conformational evaluation of p-tert-butylthiacalix[4]arene-crowns

Bridging of p-tert-butylthiacalix[4]arene afforded 1,3-dihydroxythiacalix[4]arene-monocrown-5 (3b), 1,2-alternate thiacalix[4]arene-biscrown-4 and -5 (4a,b), and 1,3-alternate thiacalix[4]arene-biscrown-5 and -6 (5a,b), depending on the metal carbonates and oligoethylene glycol ditosylates used. Starting from 1,3-dialkylated thiacalix[4]arenes, the corresponding bridging reaction gave 1,3-alternate, partial-cone, and cone conformers 10-19, depending on the substituents present. Temperature-dependent studies revealed that the conformationally flexible 1,3-dimethoxythiacalix-[4]arene-crowns 10a-c exclusively occupy the 1,3-alternate conformation. Demethylation exclusively gave the cone 1,3-dihydroxythiacalix[4]arene-crowns (3a,c), which could not be obtained by direct bridging of thiacalix[4]arene. The different structures were assigned on the basis of several X-ray crystal structures and extensive 2-D 1H NMR studies.

Design and Synthesis of Oleanolic Acid Trimers to Enhance Inhibition of Influenza Virus Entry

Influenza is a major threat to millions of people worldwide. Entry inhibitors are of particular interest for the development of novel therapeutic strategies for influenza. We have previously discovered oleanolic acid (OA) to be a mild influenza hemagglutinin (HA) inhibitor. In this work, inspired by the 3D structure of HA as a homotrimeric receptor, we designed and synthesized 15 OA trimers with different linkers and central region via the copper-catalyzed azide-alkyne cycloaddition reaction. All of the OA trimers were evaluated for their antiviral activities in vitro, and 12c, 12e, 13c, and 13d were observed to exhibit robust potency (IC50 in the submicromolar range) against influenza A/WSN/33 (H1N1) virus that was stronger than that observed with oseltamivir. In addition, these compounds also displayed strong biological activity against A/Hong Kong/4801/2014 and B/Sichuan/531/2018 (BV). The results of hemagglutination inhibition assays and surface plasmon resonance binding assays suggest that these OA trimers may interrupt the interaction between the HA protein of influenza virus and the host cell sialic acid receptor, thus blocking viral entry. These findings highlight the utility of multivalent OA conjugates to enhance the ligand-target interactions in anti-influenza virus drug design and are also helpful for studying antiviral drugs derived from natural products.

Target protein degradation inducing compound, preparation method thereof and pharmaceutical composition for preventing or treating targeted protein related diseases containing the same as an active ingredient

The present invention relates to a degraducer for inducing the decomposition of target protein, a producing method thereof, and a pharmaceutical composition for preventing or treating target protein-related diseases by containing the degraducer as an active ingredient. A novel compound represented by chemical formula 1, ULB-L-PTM, by the present invention, as a degraducer compound inducing the decomposition of target protein using cereblon E3 ubiquitin ligase, is able to significantly achieve a target protein degradation-inducing activity with an excellent binding activity of a cereblon E3 ubiquitin ligase binder thereby, being able to achieve an excellent protein degradation activity by targeting protein or polypeptide related to various diseases. The bromodomain-containing pharmaceutical composition for preventing or treating protein-related diseases or conditions contains the novel compound represented by chemical formula 1 as an active ingredient and has a useful effect of providing a health functional food composition for prevention or improvement.(AA) Example 22 (nM, 24h)COPYRIGHT KIPO 2020